Company Description
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Shankar Musunuri |
Contact Details
Address: 11 Great Valley Parkway Malvern, Pennsylvania 19355 United States | |
| Phone | 484-328-4701 |
| Website | ocugen.com |
Stock Details
| Ticker Symbol | OCGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1372299 |
| CUSIP Number | 67577C105 |
| ISIN Number | US67577C1053 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research and Development |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer |
| Rita Johnson-Greene M.B.A. | Chief Financial Officer |
| Paul Staid | Executive Vice President of Operations |
| John Kouch J.D. | General Counsel |
| Tiffany J. Hamilton M.B.A. | AVice President and Head of Corporate Communications |
| Kristen Craft | Head of People and Culture |
| Dr. Vijay Tammara Ph.D. | Chief Development Officer |
| Jyothy Pillai M.S. | Vice President and Head of Regulatory & Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 5, 2026 | 8-K | Current Report |
| May 4, 2026 | 8-K | Current Report |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | PRER14A | Filing |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 14, 2026 | SCHEDULE 13G | Filing |